MARKET

UTHR

UTHR

United Therapeutics Corp.
NASDAQ
223.58
-3.45
-1.52%
Closed 16:05 02/26 EST
OPEN
225.93
PREV CLOSE
227.03
HIGH
228.57
LOW
221.61
VOLUME
355.86K
TURNOVER
0
52 WEEK HIGH
261.54
52 WEEK LOW
204.44
MARKET CAP
10.52B
P/E (TTM)
11.28
1D
5D
1M
3M
1Y
5Y
United Therapeutics Filed Motion In U.S. District Court For The District Of Delaware For Preliminary Injunction In Its Patent Litigation With Liquidia Technologies' Efforts To Seek FDA Approval For PH-ILD For Its Inhaled Treprostinil Product-8K
Liquidia's investigational product is currently tentatively approved by the FDA for the treatment of pulmonary arterial hypertension but not PH-ILD. The company alleges that Liquidia’s product infringes its U.S. Patent for pulmonary hypertension associated with interstitial lung disease.
Benzinga · 17h ago
United Therapeutics Corporation to Present at the TD Cowen 44th Annual Health Care Conference
United Therapeutics Corporation is the first publicly-traded biotech or pharmaceutical company to take the form of a public benefit corporation. Michael Benkowitz will provide an overview and update on the company’s operations at the TD Cowen 44th Annual Health Care Conference in Boston. The session will take place on March 5, 2024.
Barchart · 1d ago
Weekly Report: what happened at UTHR last week (0219-0223)?
Weekly Report · 1d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Exact Sciences (EXAS), United Therapeutics (UTHR) and Ionis Pharmaceuticals (IONS)
Companies in the Healthcare sector have received a lot of coverage from analysts. Exact Sciences, United Therapeutics and Ionis Pharmaceuticals have been recommended by analysts. The analysts maintain a Buy rating on Exacts Sciences and a Hold on Ionis pharmaceuticals. The company’s shares closed at $57.53 today.
TipRanks · 2d ago
United Therapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Line
United Therapeutics (NASDAQ:UTHR) reported higher-than-expected revenues in the last quarter. The company's shares are up 1.4% from a week ago. Revenue exceeded analyst estimates by 1.6%. Revenue is forecast to grow 7.5% in the next 3 years.
Simply Wall St · 4d ago
United Therapeutics (UTHR) Q4 Earnings & Sales Beat Estimates
NASDAQ · 5d ago
Wall Street Analysts Think United Therapeutics (UTHR) Could Surge 32.73%: Read This Before Placing a Bet
NASDAQ · 5d ago
Beyond The Numbers: 4 Analysts Discuss United Therapeutics Stock
United Therapeutics specializes in drug development for pulmonary arterial hypertension. The company has been analyzed by 4 analysts in the last three months. The average price target is $288.25 for the company's 12-month share price. United Therapeutic's revenue growth over the past three months has been lower than the industry average.
Benzinga · 5d ago
More
About UTHR
United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Tyvaso (treprostinil) Inhalation Solution (Tyvaso), which includes the Tyvaso Inhalation System; Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso and Tyvaso DPI are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin), which is approved for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKinds Afrezza (insulin human) Inhalation Powder product.

Webull offers United Therapeutics Corporation stock information, including NASDAQ: UTHR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, UTHR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading UTHR stock methods without spending real money on the virtual paper trading platform.